AbCellera Biologics Inc. (ABCL)

4,0400 -0,0700 (-1,70%) Börsenschluss: 04:00PM EDT

AbCellera Biologics Inc.

2215 Yukon Street
Vancouver, BC V5Y 0A1
Canada
604-559-9005
https://www.abcellera.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 586

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Carl L.G. Hansen Ph.D.	CEO, President & Chairperson	714,94k	N/A	1975
Mr. Andrew Booth M.B.A.	Chief Financial Officer	674,55k	N/A	1974
Dr. Veronique Lecault Ph.D.	COO & Director	650,59k	1,41M	1985
Mr. Tryn T. Stimart Esq., J.D., M.Sc.	Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer	667,69k	N/A	1970
Marcie Thiessen CPA, CGA	Senior Director of Finance & Accounting	N/A	N/A	N/A
Dr. Ester Falconer Ph.D.	Chief Technology Officer	N/A	N/A	1975
Kathleen Reid B.A.	Head of Corporate Communications	N/A	N/A	N/A
Graham Craig M.Sc.	Director of Corporate Development	N/A	N/A	N/A
Mr. Murray McCutcheon Ph.D.	Senior Vice President of Partnering	N/A	N/A	N/A
Mr. Neil Aubuchon B.A., M.B.A.	Chief Commercial Officer	684,81k	N/A	1971

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Corporate Governance

AbCellera Biologics Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 10, Shareholderrechte: 4, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.